Gem Aromatics Ltd Q1 FY27 Earnings Call Summary

Event Participants

Executives

2
Yash Parekh (Managing Director & CEO), Aditya Shah (CEO's Office)

Analysts

6
Rushabh Duggad (Finovative Financials), Dhruv Shah (JJ Holdings), Omkar Dandekar (3A Capital Service), Rupesh Dhatia (Longevity Partners), Sahil Goel (Equinox Capital Venture), Varun Shivram (Choice Securities)

Financials & KPIs

Geographic & Segment Commentary

• Clove Business: Q1 FY27 impacted by cyclone-induced floods in Madagascar (March-April), causing port shutdown in Toamasina for ~30 days and delaying raw material shipments. Supply resumed from May onward; demand ramp-up expected strong from export markets, with management expecting to be "fairly close" to planned annual numbers by year-end. Trees not damaged; production capacity structurally intact. Supply diversification spans multiple regions of Madagascar.

• Mint Business: Harvest season runs May-July; Q1 typically softer as larger mint vertical starts around May-June. Export order flow now building, with shipments in transit; some revenue deferred to Q2-Q3 as shipping challenges delayed cargo reaching final destinations. Western Hemisphere (US, Latin America) demand ramp-up is key driver.

• Crystal Ingredients (Dahed Facility): Safranal commercial production has commenced, revenue contribution expected end-Q2 FY27 and meaningful from Q3. Cooling agents (GemCool 3, GemCool 5, GemCool 23) production commenced, customer audits completed (approved by world's two largest consuming companies), initial orders secured with meaningful contribution from Q3 FY27. Phenol derivatives trial production expected end-Q2, commercial production targeted Q3, meaningful revenue from Q4 FY27, subject to approvals.

Company-Specific & Strategic Commentary

• Product Diversification: Core strategy is reducing dependence on traditional mint portfolio by building balanced mix across non-mint and higher-value specialty products. Every new product is expected to be margin-accretive relative to existing portfolio. Multiple new products across specialty chemistries are in various stages of customer approvals.

• Multi-Purpose Manufacturing Platform: Dahed facility provides flexibility to respond to evolving customer requirements across different specialty chemistries, supporting broader specialty product portfolio. Strong R&D pipeline of new aroma chemicals products ready and in different execution stages.

• International Expansion: Company approved incorporation of a Brazil subsidiary — a dedicated platform for essential oils, aromatic chemicals, and specialty chemicals — representing a strategic step toward expanding distribution reach in Latin America.

• Commercialization Playbook: For phenol derivatives and other new verticals, management is targeting both large MNC end customers and faster-moving traders/distributors across geographies to accelerate revenue build-up while longer qualification cycles with large customers progress.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Core Business Demand & Seasonality

• Question: Given growth in a seasonally weak quarter, where is demand coming from in the core business and geographies? (Varun Shivram, Choice Securities)
• Answer: Demand is back to normal levels; Western Hemisphere (US, Latin America) demand ramping up. Q1 traditionally softer as mint harvest starts around May-June. Export-driven growth will reflect in Q2-Q3. (Yash Parekh)

Crystal Ingredients Vertical Milestones

• Question: What are key operational milestones before the business moves into consistent volume phase? (Varun Shivram, Choice Securities)
• Answer: Customer approvals from large MNCs are the critical gating factor. Customers start with smaller trial orders to check stability before larger orders. Cooling agents already approved by the world's two largest consuming companies. Meaningful contributions expected from Q3-Q4. (Yash Parekh)

Phenol Derivatives Timeline & Qualification Cycle

• Question: Should revenue contribution from phenol derivatives build progressively with meaningful contribution toward Q4 FY27 or FY28? (Rushabh Duggad, Finovative Financials)
• Answer: Correct — trial production end-Q2, approvals and quality processes, export revenue generation by Q3, more meaningful contribution by Q4. Pilot batches already approved; targeting both end customers (MNCs) and faster-moving traders/distributors to accelerate adoption. (Yash Parekh)

Revenue Ramp-Up Pace Across New Verticals

• Question: How should investors think about overall pace of revenue ramp-up across new verticals? (Rushabh Duggad, Finovative Financials)
• Answer: FY27 is a ramp-up year with verticals starting one by one. All verticals will commence in FY27, but meaningful ramp-up will happen in FY28 — "significant bit of revenue coming to the next financial year." Through FY28, Crystal products will be more than 50% of overall revenue. (Aditya Shah)

Margin Recovery Drivers & Product Mix Bifurcation

• Question: What are key drivers for margin recovery given Q1 pressure from product mix, raw material costs, and new facility operating costs? (Rushabh Duggad, Finovative Financials)
• Answer: Production ramp-up is the key driver, coupled with shift toward value-added products across value chains. Multi-purpose plant and robust specialty product pipeline (large number of aroma chemicals ready) will meaningfully contribute. Company declined to provide FY27 margin guidance or revenue/margin bifurcation; guidance to come as year progresses. (Yash Parekh; Aditya Shah)

Path to Consolidated Profitability

• Question: How should investors think about the path toward sustainable consolidated profitability given the loss and higher depreciation? (Dhruv Shah, JJ Holdings)
• Answer: The answer lies in commercialization of new products — it's a timing mismatch where costs (depreciation, interest, manpower) have kicked in for standby capacity but higher-margin product revenue has not yet arrived. Profitability will increase as revenue from Crystal products comes in. Working capital cycle for Crystal will be lower than traditional business given synthetic products don't require large inventory holding; factoring services will also reduce debtor days. (Aditya Shah)

Eugenol Ramp-Up & Madagascar Supply Impact

• Question: With the Madagascar flooding and supply chain disruption, is the eugenol/eugenol derivatives ramp-up delayed materially? Also, does uprooted trees (10-year recovery) imply structurally tighter margins and higher realizations? (Rupesh Dhatia, Longevity Partners)
• Answer: Impact was limited to the beginning of the year; ports reopened and material is flowing. Year-end expectations remain "fairly close" to planned numbers for eugenol. Clove tree recovery takes ~2-3 years (not 10) as oil is extracted from leaves and stems. Trees are still intact, sourcing is diversified across Madagascar regions — no major structural challenge to long-term crude availability. (Yash Parekh)

Cooling Agents Capacity Utilization Outlook

• Question: With two customer approvals, when does commercial supply to the second customer start, and can ~25% utilization on 500-ton capacity be expected this year? (Rupesh Dhatia, Longevity Partners)
• Answer: Company should be "fairly close" to those numbers, with revenue expected in Q3-Q4. Shipping challenges to Western Hemisphere are a concern, but a large part of that number should show up by Q3-Q4. (Yash Parekh)

Order Quantification & Margin Profile of New Products

• Question: Can you quantify the orders secured for GemCool products and are new products higher margin than existing? (Sahil Goel, Equinox Capital Venture)
• Answer: Order values and customer names not disclosed; clarity expected as quarters pass. Every new product is intentionally more margin-accretive than existing products. A large pipeline of value-added products is in different stages of approvals, with specialty revenue starting from Q3-Q4. (Aditya Shah; Yash Parekh)

Tariff Restocking Impact & Export Revenue Recognition

• Question: Management was positive on restocking due to tariff relief in Q4 FY26, with expectations Q1 FY27 would reflect that growth — but growth was average. What's the view and status of customer discussions? (Omkar Dandekar, 3A Capital Service)
• Answer: Q1 was impacted by harvest season (May-June for mint), Madagascar delays, and shipping challenges out of India. Exports shipped in May-June could not be accounted as they hadn't reached final destinations; some reached in July-August and will reflect accordingly. Demand is coming back for core and newer products largely in export markets. (Yash Parekh)

Currency Impact on Competitiveness

• Question: Does rupee depreciation provide a competitive pricing advantage to boost export sales? (Omkar Dandekar, 3A Capital Service)
• Answer: No tactical advantage for products with imported inputs (clove, phenol, citral, cooling agents process imports then re-export). Company hedges foreign contracts on export realizations. Pure-play Indian origin products like mint benefit, but overall mixed portfolio neutralizes any currency advantage or disadvantage. (Yash Parekh)

Key Takeaway

Gem Aromatics reported Q1 FY27 standalone revenue of ₹83 crores (+9.2% YoY) and consolidated revenue of ₹99 crores (+12.5% YoY), supported by improving business activity despite a seasonally soft quarter. Consolidated EBITDA margins contracted to 3.3% and the company reported a consolidated loss of ₹7.9 crores, driven by ₹9.1 crores depreciation from the capitalized Dahed facility and clove raw material disruption following Madagascar floods. The Dahed facility commercialization is progressing across three verticals — cooling agents (approved by the world's two largest consumers, meaningful contribution from Q3 FY27), safranal (revenue from end-Q2), and phenol derivatives (commercial production targeted Q3, meaningful revenue Q4) — with FY27 framed as a ramp-up year and Crystal expected to exceed 50% of revenue in FY28. A Brazil subsidiary has been approved to expand Latin American distribution. Management declined interim FY27 guidance, citing ongoing product qualification cycles and the need for accuracy, but expects operating leverage to progressively support margins as utilization improves and new specialty products scale. Key watch points include customer approval timelines for new verticals, Madagascar clove supply normalization, and shipping-related revenue recognition timing.